Anti-Mouse CD96 – Purified in vivo PLATINUM™ Functional Grade

Clone 3.3 refers to a monoclonal antibody (mAb) against mouse CD96, and it is specifically used in in vivo mouse studies to investigate immune modulation, particularly in cancer models.

In these in vivo studies, clone 3.3 is administered to mice to block the function of CD96 (also known as TACTILE), a receptor expressed on natural killer (NK) cells and T cells. By blocking CD96, researchers can study its effects on NK- and T-cell-mediated immune responses, especially in the context of tumor growth and metastasis. Experimental evidence shows that using the 3.3 antibody suppresses primary tumor growth in various mouse tumor models, supporting its role as a potential tool for cancer immunotherapy research.

Key details of use:

• CD96 blocking in vivo (and in vitro) to assess its contribution to tumor immunity and metastasis.
• Used in mice with experimental tumors to analyze how altering CD96 signaling affects tumor progression.
• The antibody is formulated specifically for in vivo use (high purity, low endotoxin, no preservatives) to ensure safety and efficacy in animal studies.

Additional applications may include flow cytometry for immunophenotyping and mechanistic studies of NK or T cell function, but the primary referenced use in vivo is for functional blockade of CD96 in experimental cancer models.

The protein 3.3 commonly refers to 14-3-3 proteins, which are a family of regulatory molecules widely studied in cell biology and therapeutic research. In studies involving 14-3-3 proteins, researchers frequently use a variety of antibodies and proteins for detection, functional analysis, and interaction mapping.

Commonly used antibodies or proteins with 14-3-3 (3.3) include:

• Isoform-Specific Antibodies: Antibodies targeting specific 14-3-3 isoforms, such as 14-3-3?, 14-3-3?, 14-3-3?, etc., are frequently used to distinguish isoform-specific roles and distributions.
• Phospho-Specific Antibodies: Because 14-3-3 proteins often bind phosphorylated motifs on target proteins, phospho-specific antibodies (e.g., anti-phospho-Ser/Thr antibodies) are used to study interactions and signaling events.
• Common Partner Proteins:
  • Kinases (such as RAF and AKT), since 14-3-3 proteins modulate kinase activity.
  • Transcription factors and apoptotic regulators, which are known direct partners of 14-3-3.
• IgG: For detection and purification, the commonly used format of antibody is IgG, due to its stability and specificity, and it is the standard in most antibody-based assays.
• Recombinant Antibodies: These are engineered antibodies like single-chain variable fragments (scFv), VHH (nanobody), and domain antibodies, which may be utilized in fusion protein formats or multiplex assays alongside conventional 14-3-3 antibodies.
• Dual-variable-domain Antibodies & IgG–scFv Fusions: These engineered antibodies allow simultaneous targeting of 14-3-3 and an additional protein, improving specificity and functional analysis.

Additional proteins often detected or used in 14-3-3 research include associated signaling molecules, ubiquitin ligases, or downstream effectors relevant to cell cycle regulation, apoptosis, or neurobiology.

In summary, isoform-specific antibodies, phospho-specific antibodies, recombinant formats (scFv, VHH), IgG isotypes, and proteins involved in cell signaling are commonly used with 14-3-3 proteins in the literature.

Key findings from "clone 3.3" citations in scientific literature are limited and context-dependent, but the most relevant data available come from studies using or referencing the Llama 3.3 large language model and versions of 'CLONE' in clinical reasoning.

• CLONE 3.3 (Llama 3.3) in Clinical Reasoning: CLONE’s integration with large models like Llama 3.3 (70B) led to improved diagnostic accuracy and enhanced performance for general-purpose machine learning models in clinical settings. This suggests that “clone 3.3” models can translate guideline-based reasoning into more effective AI-driven diagnosis.

• Applications of RNNs in Code Clone Detection: Although not a direct citation of "clone 3.3," a systematic review highlights a surge (after 2020) in the use of recurrent neural network (RNN) techniques for detecting code clones, supporting significant advances in automated analysis and machine learning for software reliability.

• Citation Reliability and Ethical Concerns: Reviews of scientific citations note frequent citation inaccuracies, including the misattribution or inappropriate referencing of cloning or computational models, which can distort scientific narratives and impact credibility. Additionally, ethical debates in the literature around human cloning emphasize concerns about personhood, reproductive freedom, and the pursuit of scientific advancement.

In summary, the most clearly documented key finding from citations to "clone 3.3" involves its role in raising diagnostic accuracy with large-scale clinical AI models. Broader trends in code clone research, citation quality, and bioethics are relevant but must be interpreted in context and do not directly address "clone 3.3" itself.

Dosing regimens of clone 3.3 can vary significantly depending on the specific mouse model used, the experimental goal (such as cell depletion or immune activation), and the target antigen; however, available search results do not provide direct information on clone 3.3 dosing schedules in different mouse models.

Key points based on general antibody dosing for mouse models:

• Antibody dosing regimens (for other clones) can range from 100–300??g per mouse, with administration routes typically intraperitoneal injection and dosing intervals every 3 days or 1–3 times per week, depending on the antibody’s pharmacokinetics and the desired biological effect.
• Choice of mouse strain or model (e.g., BALB/c vs. C3HeB/FeJ) can influence dosing strategies and outcomes, especially for agents affecting the immune system, due to variability in immune background, susceptibility to disease, or target epitope expression. In some regimens, higher or more frequent dosing may be required in strains with higher target cell numbers or more aggressive disease phenotypes.
• Databases like ROADMAPS provide specific dosing regimens for various antibodies and agents across many mouse models, but specific information for clone 3.3 is not included in the provided results.

If you require exact dosing regimens for clone 3.3:

• Check the supplier datasheet or published literature for the specific antibody clone and application (e.g., depletion, blockade, activation).
• Use general antibody dosing guidelines as a starting point: typically, 100–250??g per mouse, every 3 days by intraperitoneal injection.
• Adjust dose and schedule based on pilot studies in your target mouse model, monitoring biological effect and tolerability.

Summary table: General Antibody Dosing in Mouse Models
| Antibody Clone | Dose Range (?g/mouse) | Dosing Interval | Route | Notes ||----------------|-----------------------|------------------------|-------------------|---------------------|| 9H10 (Anti-CTLA-4) | 100–200 | Every ~3 days | Intraperitoneal | Checkpoint blockade || 1A8 (Anti-Ly6G) | 100–250 | 3x/week or every 3 days | Intraperitoneal | Neutrophil depletion|| PK136 (Anti-NK1.1) | 200–300 | 1–3x/week | Intraperitoneal | NK cell depletion |

If you provide the target or application for clone 3.3, or if it is a well-characterized antibody, more specific guidance can be obtained from literature or supplier technical sheets. General dosing strategies outlined above should be adapted and validated for your chosen mouse strain and disease model.